Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENCEFALO: encorafenib + binimetinib followed by cemiplimab + fianlimab in BRAF-mutated melanoma with symptomatic brain metastases
2024-513375-40-00Phase 2Authorised
- Sponsor
- Gem
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib, binimetinib, cemiplimab and fianlimab in melanoma, sponsored by Gem. Primary endpoint: 6-month intracranial progression-free survival (icPFS). Planned start Apr 2025; status: authorised.
02
Drugs
encorafenibbinimetinibcemiplimabfianlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-513375-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513375-40-00.